(a)
|
|
Net asset value returns
|
1 year
|
5 years
|
10 years
|
Total Return Securities Fund
|
11.18%
|
7.67%
|
6.62%
|
Market price returns
|
|||
Total Return Securities Fund
|
21.21%
|
10.29%
|
7.84%
|
Index returns
|
|||
S&P 500 Index
|
15.16%
|
16.64%
|
13.65%
|
Share price as of 6/30/25
|
|||
Net asset value
|
$7.13
|
||
Market price
|
$6.34
|
Schedule of Investments by Industry (Unaudited)
|
June 30, 2025
|
Shares
|
Value
|
|||||||
COMMON STOCKS — 39.2%
|
||||||||
Banking — 0.3%
|
||||||||
PB Bankshares, Inc. (a)
|
13,863
|
$
|
244,959
|
|||||
Financial Services — 3.6%
|
||||||||
Cannae Holdings, Inc.
|
160,000
|
3,336,000
|
||||||
Food & Beverage — 12.3%
|
||||||||
Aryzta AG (a)
|
25,000
|
2,539,259
|
||||||
Nestle SA
|
90,000
|
8,912,940
|
||||||
11,452,199
|
||||||||
Healthcare — 1.8%
|
||||||||
Spineart SA (a)(b)
|
221,085
|
1,680,357
|
||||||
Oil, Gas & Consumable Fuels — 1.0%
|
||||||||
Texas Pacific Land Corp.
|
900
|
950,751
|
||||||
Real Estate Investment Trusts — 5.1%
|
||||||||
Alexander's, Inc.
|
21,041
|
4,740,958
|
||||||
Real Estate Management & Development — 4.8%
|
||||||||
Tejon Ranch Co. (a)
|
260,000
|
4,409,600
|
||||||
Retail — 10.3%
|
||||||||
Cie Financiere Richemont SA
|
40,000
|
7,510,050
|
||||||
Village Super Market, Inc. — Class A
|
52,742
|
2,030,567
|
||||||
9,540,617
|
||||||||
TOTAL COMMON STOCKS
|
||||||||
(Cost $24,307,223)
|
36,355,441
|
|||||||
CLOSED-END FUNDS — 5.7%
|
||||||||
Central and Eastern Europe Fund, Inc.
|
13,374
|
207,565
|
||||||
Central Securities Corp.
|
105,000
|
5,025,300
|
||||||
TOTAL CLOSED-END FUNDS
|
||||||||
(Cost $4,866,696)
|
5,232,865
|
Schedule of Investments by Industry (Unaudited)
|
June 30, 2025
|
Units/Shares
|
Value
|
|||||||
MASTER LIMITED PARTNERSHIPS — 0.5%
|
||||||||
Biotechnology — 0.5%
|
||||||||
Aravis Biotech II, Limited Partnership (a)(b)
|
3,294,705
|
$
|
459,810
|
|||||
TOTAL MASTER LIMITED PARTNERSHIPS
|
||||||||
(Cost $213,885)
|
459,810
|
|||||||
SHORT-TERM INVESTMENTS — 53.0%
|
||||||||
Money Market Funds — 53.0%
|
||||||||
Fidelity Government Portfolio — Institutional Class, 4.22%(c)(d)
|
24,570,789
|
24,570,789
|
||||||
Invesco Treasury Portfolio — Institutional Class, 4.23%(c)(d)
|
24,548,855
|
24,548,855
|
||||||
TOTAL SHORT-TERM INVESTMENTS
|
||||||||
(Cost $49,119,644)
|
49,119,644
|
|||||||
TOTAL INVESTMENTS — 98.4%
|
||||||||
(Cost $78,507,448)
|
91,167,760
|
|||||||
Other Assets in Excess of Liabilities — 1.6%
|
1,502,558
|
|||||||
TOTAL NET ASSETS — 100.0%
|
$
|
92,670,318
|
(a)
|
Non-income producing security.
|
(b)
|
Fair value determined using significant unobservable inputs in accordance with procedures established by and under the supervision of the Fund’s Board of Directors. These
securities represented $2,140,167 or 2.3% of net assets as of June 30, 2025.
|
(c)
|
The rate shown represents the 7-day annualized effective yield as of June 30, 2025.
|
(d)
|
Fair value of this security exceeds 25% of the Fund’s net assets. Additional information for this security, including the financial statements, is available from the SEC’s
EDGAR database at www.sec.gov.
|
1
|
Illiquid. There is not a public market for these securities in the United States or in any foreign jurisdiction, including Switzerland. Securities are priced at Fair Value
in accordance with the Fund’s valuation policy and procedures. At the end of the period, the aggregate Fair Value of these securities amounted to $2,140,167 or 2.3% of the Fund’s net assets. Additional information on these securities is as
follows:
|
Security
|
Acquisition Date
|
Cost
|
|||
Aravis Biotech II, Limited Partnership
|
July 31, 2007 – May 29, 2018
|
$
|
213,885
|
||
Spineart SA – Common Shares
|
December 22, 2010 – December 20, 2020
|
1,554,486
|
|||
$
|
1,768,370
|
Schedule of Investments by Industry (Unaudited)
|
June 30, 2025
|
(concluded)
|
2
|
Affiliated Company. An affiliated company is a company in which the Fund has ownership of at least 5% of the company’s outstanding voting securities or an equivalent interest
in the company. Details related to affiliated company holdings are as follows:
|
Value
|
Change in
|
Value
|
||||||||||||||||||||||||||||||
as of
|
Gross
|
Gross
|
Corporate
|
Realized
|
Unrealized
|
Interest
|
as of
|
|||||||||||||||||||||||||
Name of Issuer
|
12/31/24
|
Additions
|
Reductions
|
Actions
|
Gain/(Loss)
|
Gain/(Loss)
|
Income
|
6/30/25
|
||||||||||||||||||||||||
Aravis Biotech II,
|
||||||||||||||||||||||||||||||||
Limited Partnership
|
$
|
427,248
|
$
|
—
|
$
|
—
|
$
|
—
|
$
|
—
|
$
|
32,562
|
$
|
—
|
$
|
459,810
|
||||||||||||||||
$
|
427,248
|
$
|
—
|
$
|
—
|
$
|
—
|
$
|
—
|
$
|
32,562
|
$
|
—
|
$
|
459,810
|
PORTFOLIO HOLDINGS
|
||
% of Net Assets as of June 30, 2025
|
||
Banking
|
0.30%
|
|
Food & Beverage
|
12.30%
|
|
Healthcare
|
1.80%
|
|
Financial Services
|
3.60%
|
|
Oil, Gas & Consumable Fuels
|
1.00%
|
|
Real Estate Management & Development
|
4.80%
|
|
Real Estate Investment Trusts
|
5.10%
|
|
Retail
|
10.30%
|
|
Closed-End Funds
|
5.70%
|
|
Biotechnology
|
0.50%
|
|
Money Market Funds
|
53.00%
|
|
Other Assets Less Liabilities
|
1.60%
|
|
100.00%
|
||
TOP 10 PORTFOLIO HOLDINGS
|
||
% of Net Assets as of June 30, 2025
|
||
Nestle SA
|
9.63%
|
|
Cie Financiere Richemont SA
|
8.11%
|
|
Central Securities Corp
|
5.43%
|
|
Alexanders Inc
|
5.12%
|
|
Tejon Ranch Co
|
4.76%
|
|
Cannae Holdings Inc
|
3.60%
|
|
ARYZTA AG
|
2.74%
|
|
Village Super Market Inc
|
2.19%
|
|
SPINEART SA
|
1.81%
|
|
Texas Pacific Land Corp
|
1.03%
|
Statement of Assets and Liabilities (Unaudited)
|
June 30, 2025
|
Assets:
|
||||
Investments in unaffiliated issuers, at value (cost $29,144,617)
|
$
|
41,588,306
|
||
Investments in affiliated issuers, at value (cost $213,885)
|
459,810
|
|||
Total Investments, at value (cost $29,358,502)
|
42,048,116
|
|||
Cash and cash equivalents
|
49,141,578
|
|||
Foreign currency (cost $0)
|
4,932
|
|||
Tax reclaims receivable
|
1,699,139
|
|||
Dividend receivable
|
17,063
|
|||
Interest receivable
|
142,652
|
|||
Prepaid expenses
|
149,034
|
|||
Total assets
|
93,202,514
|
|||
Liabilities:
|
||||
Accrued Fees and Expenses:
|
||||
Payable for investments purchased
|
476,866
|
|||
Investment advisory
|
6,497
|
|||
Directors
|
66,290
|
|||
Miscellaneous
|
21,899
|
|||
Audit
|
15,054
|
|||
Officer
|
11,041
|
|||
Custody
|
6,158
|
|||
Credit facility interest
|
4,784
|
|||
Total liabilities
|
608,589
|
|||
Net assets
|
$
|
92,593,925
|
||
Composition of Net Assets:
|
||||
Par value
|
12,991
|
|||
Paid-in capital
|
82,695,148
|
|||
Total distributable earnings
|
9,885,786
|
|||
Net assets
|
$
|
92,593,925
|
||
Net Asset Value Per Share:
|
||||
($92,593,738 ÷
shares outstanding, |
||||
$0.001 par value:
million shares authorized) |
$
|
|
Statement of Operations (Unaudited)
|
For the Six Months Ended June 30, 2025
|
Investment Income:
|
||||
Dividend (less of foreign tax withheld of $180,788)
|
$
|
1,818,833
|
||
Interest income
|
580,716
|
|||
Total income
|
2,399,549
|
|||
Expenses:
|
||||
Investment advisory fees (Note 2)
|
386,879
|
|||
Directors’
|
165,058
|
|||
Officers
|
67,372
|
|||
Administration (Note 3)
|
62,662
|
|||
Legal (Note 3)
|
75,381
|
|||
Printing and shareholder reports
|
28,690
|
|||
Audit (Note 3)
|
15,802
|
|||
LOC Commitment
|
23,221
|
|||
Custody (Note 3)
|
26,524
|
|||
Insurance
|
25,473
|
|||
Transfer agency (Note 3)
|
15,551
|
|||
Miscellaneous
|
70,640
|
|||
Total expenses
|
963,253
|
|||
Net investment income
|
1,436,296
|
|||
Realized and Unrealized Gains (Losses) on Investments and Foreign Currency Translations:
|
||||
Net realized gain (loss) from:
|
||||
Investments in unaffiliated issuers
|
39,634,207
|
|||
Foreign currency transactions
|
(115,272
|
)
|
||
Total net realized gain (loss) from unaffiliated and affiliated
|
||||
issuers and foreign currency transactions
|
39,518,935
|
|||
Net change in unrealized appreciation (depreciation) from:
|
||||
Investments in unaffiliated issuers
|
(23,924,214
|
)
|
||
Investments in affiliated issuers
|
32,562
|
|||
Foreign currency translations
|
227,856
|
|||
Total net change in unrealized appreciation (depreciation) from
|
||||
unaffiliated and affiliated issuers, and foreign currency translations
|
(23,663,796
|
)
|
||
Net Realized and Unrealized Gain (Loss) on
|
||||
Investments and Foreign Currency Translations
|
15,855,139
|
|||
Net Decrease in Net Assets from Operations
|
$
|
17,291,435
|
Statement of Cash Flows (Unaudited)
|
For the Six Months Ended June 30, 2025
|
Cash flows from operating activities:
|
||||
Net decrease in net assets applicable to common shareholders
|
$
|
17,291,435
|
||
Adjustments to reconcile net increase in net assets applicable to
|
||||
common shareholders resulting from operations to net cash
|
||||
provided by operating activities:
|
||||
Purchases of investments
|
(21,660,583
|
)
|
||
Proceeds from sales of investments
|
108,417,687
|
|||
Increase in tax reclaims receivable
|
(429,332
|
)
|
||
Increase in dividends and interest receivable
|
(155,181
|
)
|
||
Increase in other assets
|
(131,468
|
)
|
||
Increase in payable for investments purchased
|
476,866
|
|||
Decrease in payable to Adviser
|
(63,273
|
)
|
||
Decrease in accrued expenses and other liabilities
|
(98,593
|
)
|
||
Net realized gains from investments
|
(39,617,144
|
)
|
||
Net change in unrealized (appreciation) depreciation from investments
|
23,891,652
|
|||
Net cash provided by operating activities
|
87,922,066
|
|||
Cash flows from financing activities:
|
||||
Distributions paid to common shareholders
|
(40,866,160
|
)
|
||
Net cash used in financing activities
|
(40,866,160
|
)
|
||
Net change in cash
|
$
|
47,055,906
|
||
Cash:
|
||||
Beginning of period*
|
2,090,604
|
|||
End of period*
|
$
|
49,146,510
|
||
Cash financing activities not included herein consist of interest paid
|
—
|
For the
|
||||||||
Six Months Ended
|
For the
|
|||||||
June 30, 2025
|
Year Ended
|
|||||||
(Unaudited)
|
December 31, 2024
|
|||||||
Increase (Decrease) in Net Assets:
|
||||||||
Operations:
|
||||||||
Net investment income
|
$
|
1,436,296
|
$
|
1,317,822
|
||||
Total net realized gain (loss) from unaffiliated and
|
||||||||
affiliated issuers and foreign currency transactions
|
39,518,935
|
(2,728,089
|
)
|
|||||
Total net change in unrealized appreciation
|
||||||||
(depreciation) from unaffiliated and affiliated issuers,
|
||||||||
foreign currency and foreign currency translations
|
(23,663,796
|
)
|
(2,330,891
|
)
|
||||
Net increase (decrease) in net assets from operations
|
17,291,435
|
(3,741,158
|
)
|
|||||
Distributions to Stockholders:
|
||||||||
From earnings
|
(40,866,160
|
)
|
(1,423,836
|
)
|
||||
From return of capital
|
—
|
(5,497,612
|
)
|
|||||
Total distributions to stockholders
|
(40,866,160
|
)
|
(6,921,448
|
)
|
||||
Capital Stock Transactions:
|
||||||||
Value of shares repurchased through
|
||||||||
stock repurchase program (Note 6)
|
—
|
—
|
||||||
Total decrease from capital share transactions
|
—
|
—
|
||||||
Total increase (decrease) in net assets
|
(23,574,725
|
)
|
(10,662,606
|
)
|
||||
Net Assets:
|
||||||||
Beginning of period
|
116,168,650
|
126,831,256
|
||||||
End of period
|
$
|
92,593,925
|
$
|
116,168,650
|
For the Six
|
||||||||||||||||||||||||
Months Ended
|
||||||||||||||||||||||||
June 30, 2025
|
For the Years Ended December 31,
|
|||||||||||||||||||||||
(Unaudited)
|
2024
|
2023
|
2022
|
2021
|
2020
|
|||||||||||||||||||
Per Share Operating Performance:
|
||||||||||||||||||||||||
Net asset value at the
|
||||||||||||||||||||||||
beginning of period/year
|
$
|
8.94
|
$
|
9.76
|
$
|
8.80
|
$
|
11.50
|
$
|
10.45
|
$
|
9.71
|
||||||||||||
Income from Investment Operations:
|
||||||||||||||||||||||||
Net investment income1
|
0.11
|
0.10
|
0.07
|
0.07
|
0.05
|
0.05
|
||||||||||||||||||
Net realized and unrealized
|
||||||||||||||||||||||||
gain (loss) on investments2
|
(1.39
|
)
|
(0.39
|
)
|
1.36
|
(2.15
|
)
|
1.58
|
1.24
|
|||||||||||||||
Total from investment activities
|
(1.28
|
)
|
(0.29
|
)
|
1.43
|
(2.08
|
)
|
1.63
|
1.29
|
|||||||||||||||
Anti-dilutive effect of common
|
||||||||||||||||||||||||
share repurchase program
|
—
|
—
|
0.03
|
—
|
4
|
—
|
0.01
|
|||||||||||||||||
Less Distributions:
|
||||||||||||||||||||||||
Net investment income
|
(0.11
|
)
|
(0.11
|
)
|
(0.17
|
)
|
(0.06
|
)
|
(0.06
|
)
|
(0.08
|
)
|
||||||||||||
Net realized gains
|
—
|
—
|
(0.28
|
)
|
(0.16
|
)
|
(0.09
|
)
|
—
|
|||||||||||||||
Return of Capital
|
(0.42
|
)
|
(0.42
|
)
|
(0.05
|
)
|
(0.40
|
)
|
(0.43
|
)
|
(0.48
|
)
|
||||||||||||
Total distributions
|
(0.53
|
)
|
(0.53
|
)
|
(0.50
|
)
|
(0.62
|
)
|
(0.58
|
)
|
(0.56
|
)
|
||||||||||||
Net asset value at end of period/year
|
$
|
|
$
|
|
$
|
|
$
|
|
$
|
|
$
|
|
||||||||||||
Market value per share at the
|
||||||||||||||||||||||||
end of period/year
|
$
|
|
$
|
|
$
|
|
$
|
|
$
|
|
$
|
|
||||||||||||
Total Investment Returns:3,5
|
||||||||||||||||||||||||
Based on market value per share
|
26.34
|
%
|
-2.49
|
%
|
15.48
|
%
|
-17.62
|
%
|
18.25
|
%
|
14.18
|
%
|
||||||||||||
Based on net asset value per share
|
15.78
|
%
|
-3.20
|
%
|
16.92
|
%
|
-17.97
|
%
|
16.09
|
%
|
14.29
|
%
|
||||||||||||
Ratios to Average Net Assets:6
|
||||||||||||||||||||||||
Net expenses
|
1.74
|
%
|
1.61
|
%
|
1.66
|
%7
|
1.68
|
%7
|
1.40
|
%
|
1.80
|
%
|
||||||||||||
Gross expenses
|
1.74
|
%
|
1.61
|
%
|
1.66
|
%7
|
1.68
|
%7
|
1.40
|
%
|
1.80
|
%
|
||||||||||||
Net investment income
|
2.60
|
%
|
1.05
|
%
|
0.73
|
%
|
0.74
|
%
|
0.48
|
%
|
0.48
|
%
|
||||||||||||
Supplemental Data and Ratios
|
||||||||||||||||||||||||
Net assets at end of period/year (000’s)
|
$
|
92,594
|
$
|
116,169
|
$
|
126,831
|
$
|
116,174
|
$
|
151,912
|
$
|
138,040
|
||||||||||||
Average net assets during the year (000’s)
|
$
|
111,453
|
$
|
125,526
|
$
|
123,139
|
$
|
123,684
|
$
|
144,019
|
$
|
125,666
|
||||||||||||
Portfolio turnover rate
|
50
|
%
|
9
|
%
|
14
|
%
|
15
|
%
|
11
|
%
|
12
|
%
|
1
|
Calculated using the average shares method.
|
2
|
Includes net realized and unrealized currency gains and losses.
|
3
|
Total investment return based on market value differs from total investments return based on net asset value due to changes in the relationship between the market value of
the Fund’s shares and its NAV per share.
|
4
|
Less than 0.5 cents per share.
|
5
|
Not annualized for periods less than one year.
|
6
|
Annualized for periods less than one year.
|
7
|
If interest expense and commitment fees had been excluded, the expense ratios would have been lower by 0.05% for the years ended December 31, 2022 and December 31, 2023.
|
Level 1—
|
unadjusted quoted prices in active markets for identical assets and liabilities
|
Level 2—
|
other significant observable inputs (including quoted prices of similar securities, interest rates, prepayment speeds, credit risk, etc.)
|
Level 3—
|
significant unobservable inputs (including the Fund’s own assumptions in determining the fair value of investments)
|
Level 1
|
Level 2
|
Level 3
|
Total
|
|||||||||||||
Assets:
|
||||||||||||||||
Investments:
|
||||||||||||||||
Common Stocks
|
$
|
34,675,084
|
$
|
—
|
$
|
1,680,357
|
$
|
36,355,441
|
||||||||
Closed-End Funds
|
5,232,864
|
—
|
—
|
5,232,864
|
||||||||||||
Master Limited Partnerships
|
—
|
—
|
459,810
|
459,810
|
||||||||||||
Money Market Funds
|
49,119,644
|
—
|
—
|
49,119,644
|
||||||||||||
Total Investments
|
$
|
89,027,593
|
$
|
—
|
$
|
2,140,167
|
$
|
91,167,760
|
*
|
Please see the Schedule of Investments for industry classifications.
|
**
|
As of June 30, 2025, certain of the Fund’s investments were valued using net asset value (“NAV”) per share (or its equivalent) as a practical expedient for fair value and
have been excluded from the fair value hierarchy in accordance with ASU 2015-07. The fair value amount presented in this table is intended to permit reconciliation of the amounts presented in the fair value hierarchy to the amounts presented
in the statement of assets and liabilities.
|
Quantitative Information about certain Level 3 Fair Value Measurements
|
||||
Value at
|
||||
June 30, 2025
|
Valuation Technique
|
Unobservable Inputs
|
Range1
|
|
Healthcare-Products
|
||||
Spineart SA—Common Shares
|
$1,680,357
|
Market approach
|
Based on listed trading
|
|
multiples, cross checked to
|
||||
secondary share purchase
|
||||
with additional discount
|
||||
for lack of marketability
|
15-25%
|
|||
Total
|
$1,680,357
|
1
|
Significant changes in any of these ranges would result in a significantly higher or lower fair value measurement. A change in the discount rate is accompanied by a
directionally opposite change in fair value.
|
Common
|
Preferred
|
|||||||||||
Stock
|
Stock
|
Total
|
||||||||||
Balance as of December 31, 2024
|
$
|
1,400,307
|
$
|
—
|
$
|
1,400,307
|
||||||
Change in Unrealized Appreciation/Depreciation
|
280,050
|
—
|
280,050
|
|||||||||
Net Realized Gain (Loss)
|
—
|
—
|
—
|
|||||||||
Gross Purchases
|
—
|
—
|
—
|
|||||||||
Gross Sales
|
—
|
—
|
—
|
|||||||||
Transfer out of Level 3
|
—
|
—
|
—
|
|||||||||
Balance as of June 30, 2025
|
$
|
1,680,357
|
$
|
—
|
$
|
1,680,357
|
||||||
Change in unrealized appreciation (depreciation) during the period
|
||||||||||||
for Level 3 investments held at June 30, 2025
|
280,050
|
—
|
280,050
|
For the Period Ended
June 30, 2025
|
For the Year Ended
December 31, 2024
|
|||||||||||||||
Shares
|
Amount
|
Shares
|
Amount
|
|||||||||||||
Dividends Reinvested
|
—
|
$
|
—
|
—
|
$
|
—
|
||||||||||
Repurchased through Stock Repurchase Program (Note 6)
|
—
|
—
|
—
|
—
|
||||||||||||
Repurchased from Tender Offer
|
—
|
—
|
—
|
—
|
||||||||||||
Net Increase/(Decrease)
|
—
|
$
|
—
|
—
|
$
|
—
|
2024
|
2023
|
|||||||
Ordinary Income
|
$
|
1,423,836
|
$
|
2,489,577
|
||||
Return of Capital
|
5,497,612
|
691,968
|
||||||
Long-Term Capital Gains
|
—
|
3,306,885
|
||||||
Total
|
$
|
6,921,448
|
$
|
6,488,430
|
Tax cost of investments
|
$
|
78,268,859
|
||
Unrealized appreciation
|
42,630,452
|
|||
Unrealized depreciation
|
(7,819,583
|
)
|
||
Net unrealized appreciation
|
34,810,869
|
|||
Net unrealized on foreign currency
|
(49,352
|
)
|
||
Undistributed ordinary income
|
—
|
|||
Undistributed long-term capital gains
|
—
|
|||
Distributable earnings
|
—
|
|||
Other accumulated losses
|
(1,301,006
|
)
|
||
Total distributable earnings
|
$
|
33,460,511
|
Record Date
|
Payable Date
|
Ordinary Income
|
Return of Capital
|
ST Cap Gains
|
LT Cap Gains
|
Total Distribution
|
||||||||||||||||
3/19/24
|
3/28/24
|
$
|
0.02653705
|
$
|
0.10246295
|
$
|
—
|
$
|
—
|
$
|
0.12900
|
|||||||||||
6/18/24
|
6/28/24
|
0.02653705
|
0.10246295
|
—
|
—
|
0.12900
|
||||||||||||||||
9/19/24
|
9/30/24
|
0.02653705
|
0.10246295
|
—
|
—
|
0.12900
|
||||||||||||||||
12/17/24
|
12/31/24
|
0.02999304
|
0.11580696
|
—
|
—
|
0.14580
|
||||||||||||||||
$
|
0.10960421
|
$
|
0.42319579
|
$
|
—
|
$
|
—
|
$
|
0.53280
|
Original Capital
|
Unfunded
|
|
Investments
|
Commitment*
|
Commitment*
|
Private Equity Limited Partnership—International(a)
|
||
Aravis Biotech II, Limited Partnership
|
$ —
|
$ —
|
*
|
The original capital commitment represents 3,250,000 Swiss francs, which has been fully funded as of June 30, 2025. The Swiss franc/U.S. dollar exchange rate as of June 30,
2025 was used for conversion and equaled 0.9063 as of such date.
|
(a)
|
This category consists of one private equity limited partnership that invests primarily in venture capital companies in the biotechnology and medical technology sectors.
There is no redemption right for the interest in this limited partnership. Instead, the nature of investments in this category is that distributions are received through the realization of the underlying assets of the limited partnership.
|
Gross Foreign
|
Foreign Taxes
|
Gross Foreign
|
Foreign Taxes
|
Shares Outstanding
|
Source Income
|
Pass-through
|
Source Income Per Share
|
Pass-through Per Share
|
at 12/31/24
|
3,424,867
|
468,216
|
0.26363981
|
0.00901060
|
12,990,705
|
Number of
|
||||
Portfolios in
|
||||
Position(s)
|
Fund Complex
|
Other Directorships
|
||
Name,
|
with Fund
|
Principal Occupation(s)
|
Overseen
|
held by Director During
|
Address1 & Age
|
(Since)
|
During the Last Five Years
|
by Trustee**
|
At Least The Past Five Years
|
Interested Directors
|
||||
Class II
|
||||
Andrew Dakos*
|
Director (2017)
|
Partner, Bulldog Investors, LLP;
|
3
|
President and Director of
|
and
|
Partner, Ryan Heritage, LLP;
|
Special Opportunities Fund,
|
||
Age: 59
|
Chairman (2018)
|
Principal of the former general
|
Inc. since 2009; Trustee,
|
|
partner of several private
|
Crossroads Liquidating Trust
|
|||
investment partnerships in the
|
(formerly, Crossroads Capital,
|
|||
Bulldog Investors group of
|
Inc.) from 2015-2020;
|
|||
private funds; Principal of the
|
President and Trustee of
|
|||
managing general partner
|
High Income Securities
|
|||
of Bulldog Investors
|
Fund since 2018; Director,
|
|||
General Partnership
|
Brookfield DTLA Fund Office
|
|||
Trust Investor Inc. since 2017,
|
||||
BNY Mellon Municipal Income,
|
||||
Inc. from 2024-2025, and
|
||||
Tejon Ranch Co. since 2025
|
||||
Class III
|
||||
Phillip F. Goldstein*
|
Director (2018);
|
Partner of Bulldog Investors,
|
3
|
Chairman and Director of
|
Member and
|
LLP since 2009; Partner of
|
The Mexico Equity and Income
|
||
Age: 80
|
Chair of the
|
Ryan Heritage, LLP; Principal
|
Fund, Inc. since 2000;
|
|
Governance/
|
of the former general partner
|
Chairman, Director and
|
||
Nominating
|
of several private investment
|
Secretary of Special
|
||
Committee (2018)
|
partnerships in the Bulldog
|
Opportunities Fund, Inc.
|
||
Investors group of private
|
since 2009; Chairman, Trustee
|
|||
funds since 2009; Principal of
|
and Secretary of High Income
|
|||
the managing general partner
|
Securities Fund since 2018;
|
|||
of Bulldog Investors
|
Director of Brookfield DTLA
|
|||
General Partnership
|
Fund Office Trust Investor Inc.
|
|||
since 2017 and BNY Mellon
|
||||
Municipal Income, Inc. from
|
||||
2024-2025; MVC Capital, Inc.
|
||||
from 2012-2020; Trustee of
|
||||
Crossroads Liquidating Trust
|
||||
(formerly, Crossroads
|
||||
Capital, Inc.) from 2016-2020
|
Number of
|
||||
Portfolios in
|
||||
Position(s)
|
Fund Complex
|
Other Directorships
|
||
Name,
|
with Fund
|
Principal Occupation(s)
|
Overseen
|
held by Director During
|
Address1 & Age
|
(Since)
|
During the Last Five Years
|
by Trustee**
|
At Least The Past Five Years
|
Independent Directors
|
||||
Class I
|
||||
Richard Dayan
|
Director (2018);
|
President and owner of
|
1
|
Trustee of High Income
|
Member of
|
Cactus Trading since 1990
|
Securities Fund since 2018
|
||
Age: 81
|
the Audit
|
|||
Committee (2018);
|
||||
Member of the
|
||||
Governance/
|
||||
Nominating
|
||||
Committee (2018)
|
||||
Moritz Sell
|
Director (2017);
|
Principal, Edison Holdings
|
2
|
Trustee of High Income
|
Member and Chair
|
GmbH; Senior Advisor,
|
Securities Fund since 2018;
|
||
Age: 57
|
of the Audit
|
Markston International LLC
|
Director of DMF (BNY Mellon
|
|
Committee (2017);
|
until 2019; Director, Market
|
Municipal Income, Inc.) from
|
||
Lead Independent
|
Strategist and Head of
|
2024-2025, FAX (Aberdeen Asia
|
||
Director (2018)
|
Proprietary Trading (London
|
Pacific Income Fund) and FCO
|
||
Branch), Landesbank Berlin AG
|
(Aberdeen Australia Equity
|
|||
and Landesbank Berlin
|
Fund) since 2004; Director
|
|||
Holding AG (formerly,
|
of Aberdeen Greater China
|
|||
Bankgesellschaft Berlin AG)
|
Fund until 2018; Chairman
|
|||
from 1996 to 2013
|
and Director of Aberdeen
|
|||
Singapore Fund until 2018
|
||||
Class III
|
||||
Gerald Hellerman
|
Director (2018);
|
Chief Compliance Officer of
|
3
|
Director of Mexico Equity
|
Member of the
|
The Mexico Equity and
|
and Income Fund, Inc. since
|
||
Age: 87
|
Audit Committee
|
Income Fund, Inc. from 2001
|
2001; Special Opportunities
|
|
(2018); Member
|
through March 31, 2020 and
|
Fund, Inc. since 2009; Fiera
|
||
and Chair
|
Special Opportunities Fund,
|
Capital Series Trust from
|
||
of the Valuation
|
Inc. from 2009 through
|
2017-2023; Trustee of High
|
||
Committee (2025)
|
March 31, 2020; Managing
|
Income Securities Fund since
|
||
Director of Hellerman
|
2018; MVC Capital, Inc.
|
|||
Associates (a financial
|
from 2003-2020; Trustee
|
|||
and corporate consulting
|
of Crossroads Liquidating
|
|||
firm) since 1993 (which
|
Trust (formerly, Crossroads
|
|||
terminated activities as of
|
Capital, Inc.) from 2017-2020
|
|||
December 31, 2013)
|
Officers2
|
|||
Name,
|
Position(s)
|
Term of Office and
|
Principal Occupation(s)
|
Address1 & Age
|
with Fund
|
Length of Time Served
|
During At Least The Past Five Years
|
Andrew Dakos*
|
President and
|
President and Chief
|
Partner, Bulldog Investors, LLP;
|
Chief Executive
|
Executive Officer since 2019;
|
Partner, Ryan Heritage, LLP;
|
|
Age: 59
|
Officer; Director
|
Chairman since 2018;
|
Principal of the former general
|
and Chairman.
|
Director since 2017
|
partner of several private
|
|
investment partnerships in the
|
|||
Bulldog Investors group of private
|
|||
funds; Principal of the managing
|
|||
general partner of Bulldog
|
|||
Investors General Partnership
|
|||
Thomas Antonucci*
|
Chief Financial
|
Since 2019
|
Director of Operations,
|
Officer
|
Bulldog Investors, LLP;
|
||
Age: 56
|
Chief Financial Officer
|
||
and Treasurer of Special
|
|||
Opportunities Fund; Treasurer
|
|||
of High Income Securities Fund
|
|||
Stephanie Darling*
|
Chief Compliance
|
Since 2019
|
General Counsel and Chief
|
Officer
|
Compliance Officer of Bulldog
|
||
Age: 55
|
Investors, LLP; Chief Compliance
|
||
Officer of Ryan Heritage, LLP,
|
|||
High Income Securities
|
|||
Fund, Special Opportunities Fund,
|
|||
Inc., and Mexico Equity and
|
|||
Income Fund, Inc.; Principal of The
|
|||
Law Office of Stephanie Darling;
|
|||
Editor-in-Chief of The
|
|||
Investment Lawyer
|
|||
Rajeev Das*
|
Secretary
|
Since 2019
|
Head of Trading, Bulldog
|
Investors, LLP
|
|||
Age: 56
|
1
|
The address for each Director and Executive Officer is c/o Total Return Securities Fund, 615 East Michigan Street, Milwaukee, WI 53202.
|
|
2
|
Each Executive Officer serves on a year-to-year basis for an indefinite term, until his or her successor is elected and qualified.
|
|
*
|
Messrs. Dakos, Goldstein, Antonucci, Das and Ms. Darling are considered an “interested person” of the Fund within the meaning of the 1940 Act because of their affiliation
with Bulldog Investors, LLP, the Adviser and positions as officers of the Fund.
|
|
**
|
The Fund Complex is comprised of the Fund, Special Opportunities Fund, Inc., and High Income Securities Fund.
|
Andrew Dakos
|
Gerald Hellerman1,4
|
Chairman, President and Chief Executive Officer
|
Director
|
Richard Dayan1,5
|
Thomas Antonucci
|
Director
|
Chief Financial Officer
|
Phillip Goldstein2
|
Stephanie Darling
|
Director
|
Chief Compliance Officer
|
Moritz Sell3,6
|
Rajeev Das
|
Director
|
Secretary
|
1
|
Audit Committee Member
|
2
|
Governance and Nominating Committee Chair
|
3
|
Audit Committee Chair
|
4
|
Valuation Committee Chair
|
5
|
Governance and Nominating Committee Member
|
6
|
Lead Independent Director
|
(b)
|
Not applicable.
|
(a)
|
Schedule of Investments is included as part of the report to shareholders filed under Item 1 of this Form.
|
(b)
|
Not Applicable.
|
Period
|
(a)
Total Number of
Shares (or Units)
Purchased
|
(b)
Average Price
Paid per Share
(or Unit)
|
(c)
Total Number of
Shares (or Units)
Purchased as Part
of Publicly
Announced Plans
or Programs
|
(d)
Maximum Number (or
Approximate Dollar
Value) of Shares (or
Units) that May Yet Be
Purchased Under the
Plans or Programs
|
Month #1
01/01/25-01/31/25
|
N/A
|
N/A
|
N/A
|
N/A
|
Month #2
02/01/25-02/28/25
|
N/A
|
N/A
|
N/A
|
N/A
|
Month #3
03/01/25-03/31/25
|
N/A
|
N/A
|
N/A
|
N/A
|
Month #4
04/01/25-04/30/25
|
N/A
|
N/A
|
N/A
|
N/A
|
Month #5
05/01/25-05/31/25
|
N/A
|
N/A
|
N/A
|
N/A
|
Month #6
06/01/25-06/30/25
|
N/A
|
N/A
|
N/A
|
N/A
|
Total
|
N/A
|
N/A
|
N/A
|
N/A
|
(a)
|
The Registrant’s Principal Executive Officer and Principal Financial Officer have reviewed the Registrant's disclosure controls and procedures (as defined in Rule 30a-3(c) under the Investment Company Act of 1940 (the “Act”)) as of a
date within 90 days of the filing of this report, as required by Rule 30a-3(b) under the Act and Rules 13a-15(b) or 15d‑15(b) under the Securities Exchange Act of 1934. Based on their review, such officers have concluded that the
disclosure controls and procedures are effective in ensuring that information required to be disclosed in this report is appropriately recorded, processed, summarized and reported and made known to them by others within the Registrant and
by the Registrant’s service provider.
|
(b)
|
There were no changes in the Registrant's internal control over financial reporting (as defined in Rule 30a-3(d) under the Act) that occurred during the period covered by this report that have materially affected, or are reasonably
likely to materially affect, the Registrant's internal control over financial reporting.
|
(a)
|
Not applicable.
|
(b)
|
Not Applicable.
|
(a)
|
(1) Any code of ethics or amendment thereto, that is the subject of the disclosure required by Item 2, to the extent that the registrant intends to satisfy Item 2 requirements through filing an
exhibit. Not Applicable.
|
(5)
|
Change in the registrant’s independent public accountant. Provide the information called for by Item 4 of Form 8-K under the Exchange Act (17 CFR 249.308). Unless otherwise specified by Item 4, or related to and necessary for a
complete understanding of information not previously disclosed, the information should relate to events occurring during the reporting period. There was no change in the registrant’s independent public accountant for the period covered by
this report.
|
(b)
|
Certifications pursuant to Section 906 of the Sarbanes‑Oxley Act of 2002. Furnished herewith.
|